Literature DB >> 6208124

Monoclonal antibody to HLA-A3.

A E Berger, J E Davis, P Cresswell.   

Abstract

The monoclonal antibody GAP A3 detects the HLA allospecificity A3. Reactivity of the monoclonal was in exact concordance with the presence of the A3 antigen as defined by conventional alloantisera on a panel of 59 cells from individuals with well-characterized HLA antigens. Reactivity with GAP A3 segregated with HLA-A3 in a family where three of eight siblings inherited the paternal A3 antigen. GAP A3 precipitated appropriate 44,000- and 12,000-dalton bands on SDS-polyacrylamide gels under reducing conditions from an HLA-A3-positive, but not an HLA-A3-negative B lymphoblastoid cell line. Thus, by serological, familial, and biochemical criteria, GAP A3 defines the allospecificity HLA-A3.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6208124     DOI: 10.1089/hyb.1.1982.1.87

Source DB:  PubMed          Journal:  Hybridoma        ISSN: 0272-457X


  33 in total

1.  Regulation of intracellular trafficking of human CD1d by association with MHC class II molecules.

Authors:  Suk-Jo Kang; Peter Cresswell
Journal:  EMBO J       Date:  2002-04-02       Impact factor: 11.598

2.  Human antigen-presenting cell/tumour cell hybrids stimulate strong allogeneic responses and present tumour-associated antigens to cytotoxic T cells in vitro.

Authors:  D J Dunnion; A L Cywinski; V C Tucker; A K Murray; A B Rickinson; P Coulie; M J Browning
Journal:  Immunology       Date:  1999-12       Impact factor: 7.397

3.  The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL.

Authors:  Anthony G Brickner; Anne M Evans; Jeffrey K Mito; Suzanne M Xuereb; Xin Feng; Tetsuya Nishida; Liane Fairfull; Robert E Ferrell; Kenneth A Foon; Donald F Hunt; Jeffrey Shabanowitz; Victor H Engelhard; Stanley R Riddell; Edus H Warren
Journal:  Blood       Date:  2006-01-03       Impact factor: 22.113

4.  Endogenous peptides bound to HLA-A3 possess a specific combination of anchor residues that permit identification of potential antigenic peptides.

Authors:  M DiBrino; K C Parker; J Shiloach; M Knierman; J Lukszo; R V Turner; W E Biddison; J E Coligan
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-15       Impact factor: 11.205

5.  Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes.

Authors:  W J Storkus; J Alexander; J A Payne; J R Dawson; P Cresswell
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

6.  Site-directed mutagenesis of an HLA-A3 gene identifies amino acid 152 as crucial for major-histocompatibility-complex-restricted and alloreactive cytotoxic-T-lymphocyte recognition.

Authors:  E P Cowan; M L Jelachich; J E Coligan; W E Biddison
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

7.  Human cytotoxic T-lymphocyte recognition of an HLA-A3 gene product expressed on murine L cells: the only human gene product required on the target cells for lysis is the class I heavy chain.

Authors:  E P Cowan; J E Coligan; W E Biddison
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

8.  Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes.

Authors:  L Rivoltini; K C Barracchini; V Viggiano; Y Kawakami; A Smith; A Mixon; N P Restifo; S L Topalian; T B Simonis; S A Rosenberg
Journal:  Cancer Res       Date:  1995-07-15       Impact factor: 12.701

9.  Human cytotoxic T cells stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and 1b proteins of respiratory syncytial virus.

Authors:  A H Cherrie; K Anderson; G W Wertz; P J Openshaw
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

10.  Down-regulation of HLA antigens by the adenovirus type 2 E3/19K protein in a T-lymphoma cell line.

Authors:  H Körner; H G Burgert
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.